Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.86
+0.07001.85%
Post-market: 3.860.00000.00%19:59 EST
Volume:19.05M
Turnover:72.66M
Market Cap:1.59B
PE:-3.53
High:3.91
Open:3.79
Low:3.65
Close:3.79
52wk High:4.57
52wk Low:1.64
Shares:411.96M
Float Shares:339.00M
Volume Ratio:0.60
T/O Rate:5.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0941
EPS(LYR):-1.0941
ROE:-55.50%
ROA:-27.30%
PB:2.28
PE(LYR):-3.53

Loading ...

Iovance reports 50% response rate for lifileucel TIL therapy in advanced sarcomas

Reuters
·
Feb 24

Iovance Biotherapeutics Q4 EPS $(0.18) Misses $(0.17) Estimate, Sales $86.771M Beat $80.361M Estimate

Benzinga
·
Feb 24

BRIEF-Iovance Biotherapeutics Q4 Operating Income USD -73.46 Million Vs. IBES Estimate USD -77.4 Million

Reuters
·
Feb 24

Iovance Biotherapeutics Q4 Pretax Profit USD -71.72 Million VS. Ibes Estimate USD -70.6 Million

THOMSON REUTERS
·
Feb 24

Iovance Biotherapeutics Grants Inducement Stock Options to New Employees

Reuters
·
Feb 21

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 21

Earning Preview: Iovance Biotherapeutics, Inc. this quarter’s revenue is expected to increase by 11.49%, and institutional views are bullish

Earnings Agent
·
Feb 17

Iovance Biotherapeutics Inc. published an update to their financial calendar

Reuters
·
Feb 12

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

GlobeNewswire
·
Feb 12

Does The Recent Share Price Slump Make Iovance Biotherapeutics (IOVA) Look More Attractive?

Simply Wall St.
·
Feb 07

Iovance Biotherapeutics Reports Best-in-Class Real-World Response Rates for Amtagvi in Advanced Melanoma

Reuters
·
Feb 06

Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Feb 04

Iovance Biotherapeutics (IOVA) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jan 28

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 17

Iovance Biotherapeutics (IOVA) Receives a Buy from Wells Fargo

TIPRANKS
·
Jan 16

Assessing Iovance Biotherapeutics (IOVA) Valuation After Revenue Guidance And 1,000 Patient Milestone

Simply Wall St.
·
Jan 11

Iovance Biotherapeutics Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation

Reuters
·
Jan 09

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 20, 2025

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 18, 2025

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Nov 24, 2025